Advances in Molecular Pathology

Felipe Simon, Ph.D., is currently Full Professor of the Faculty of Life Sciences in Universidad Andres Bello, at Santiago, Chile, and Researcher at the Millennium Institute of Immunology and Immunotherapy. His line of research is mainly focused on understanding the molecular mechanisms involved in systemic inflammatory syndromes, with a special interest in vascular and immune dysfunction, to identify suitable molecular targets and develop new and more efficient therapies to tackle organ damage and mortality. He has published more than 100 articles with more than 3,800 citations and has an H-index=40 (Google Scholar, 2022). He has been conferred several awards, participated as Expert Evaluator in numerous accreditation committees, and is currently Director of Research of the Faculty of Life Sciences at Universidad Andres Bello. He is Member of Chilean Society of Physiological Science and the American Physiological Society.

Carmelo Bernabeu, Ph.D., is Research Professor at the Spanish National Research Council since 2003. His scientific interest focuses on cardiovascular diseases involving endoglin, a cell surface receptor present in endothelial cells. Among them are: hereditary hemorrhagic telangiectasia (HHT), a vascular disease caused by heterozygous mutations in the endoglin gene; and preeclampsia, a disease affecting pregnant women and associated with hypertension and proteinuria, in which a pathogenic role has been described for elevated levels of a circulating form of endoglin. He has worked in different US universities and research centers, including the University of California at Los Angeles, Harvard University Medical School in Boston, and University of Utah in Salt Lake City. He has published more than 200 articles with more than 18,000 citations and has an H-index=71 (Google Scholar, 2022). He is Editor of several international journals in the area of Biomedicine and is current Member and past Chair of the Global Research and Medical Advisory Boardof the Hereditary Hemorrhagic Telangiectasia Foundation.